Aerie Pharma (AERI) Tops Q4 EPS by 176c

Aerie Pharma (NASDAQ: AERI) reported Q4 EPS of $1.09, $1.76 better than the analyst estimate of ($0.67). Revenue for the quarter came in at $32.7 million versus the consensus estimate of $31.45 million.

GUIDANCE:

Aerie Pharma sees FY2022 revenue of $130-140 million.

For earnings history and earnings-related data on Aerie Pharma (AERI) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Elastic N.V. (ESTC) Tops Q1 EPS by 12c, Beats on Revenue; offers FY27 Guidance
• HealthEquity (HQY) Tops Q2 EPS by 5c ; Offers Guidance